Novonesis chief executive Ester Baiget told CNBC on Monday that the biosolutions company is studying microbiome supplements as a possible companion for people taking GLP-1 weight-loss medicines¹.

Speaking on Squawk Box Europe, Baiget said GLP-1 drugs and dietary supplements could play complementary roles in treating obesity and supporting longer-term health¹.

She said the firm has scientific evidence that she argued will help patients on GLP-1s feel better as a companion during treatment, citing an ongoing study with Novo Nordisk, the maker of Wegovy and Ozempic¹.

Novonesis is studying what Baiget called a unique cocktail of pro-, pre- and post-biotics for patients on those Novo Nordisk medicines, CNBC reported¹.

CNBC said the products differ from protein and vitamin pills and that any potential benefit for GLP-1 users has yet to be established¹.

Some research has linked GLP-1 treatment to insufficient protein intake and deficiencies in certain vitamins and minerals, but CNBC said it remains unclear how much the medications themselves are responsible¹.

A PwC survey of U.K. adults, as cited by CNBC, found about 70% of GLP-1 users spending less on snacks and 40% spending more on vitamins and supplements¹.

Grand View Research, cited by CNBC, valued the global dietary supplements market at about $209.5 billion in 2025 and projected $431.7 billion by 2033; it put probiotic supplements at about $10.5 billion in 2025¹.

Novonesis, formed by the 2024 merger of Novozymes and Chr. Hansen, reported an 8% decline in organic sales in its human health business in the third quarter, CNBC said, citing weaker probiotic demand through offline channels in North America¹.

Human health accounts for about 11% of Novonesis sales, with about a third of total sales from North America, according to the report¹.

Not medical advice.

Sources

1. CNBCCould supplements be the next big opportunity in the GLP-1 weight-loss drug boom?8:27 AM

Read the original at CNBC ↗